Virological, Weight, and Drug Resistance Outcomes Among Patients Initiating a Dolutegravir-based First-line Antiretroviral Therapy Regimen in Zimbabwe

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2024 Jan 16

PMID 38227596

Authors

Vinie Kouamou

Tendai Washaya

Tichaona Mapangisana

Chiratidzo Ellen Ndhlovu

Justen Manasa

Affiliations

Soon will be listed here.

Abstract

Objective: Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up in Africa. However, clinical experience with DTG and patterns of HIV drug resistance (HIVDR) are sparse in Zimbabwe. We assessed virological, weight, and HIVDR outcomes among individuals initiating on a DTG-based ART.

Design: We conducted a prospective cohort study among HIV-infected adult (≥18 years old) individuals attending care at Parirenyatwa hospital, Harare, Zimbabwe between October 2021 and April 2023.

Methods: Viral load and weight were assessed at both baseline and follow-up (≥24weeks) visits. HIVDR genotyping was performed by Sanger sequencing among participants with virological failure (viral load ≥1000 copies/ml) at follow-up visit. Factors associated with weight gain were determined using logistic regression analysis on STATA 17.0.

Results: One hundred and seventy-two participants were enrolled in the study. The median [interquartile range (IQR) age was 39 (29-48)] years whilst the median (IQR) CD4 + cell count and log 10 viral load at enrolment was 175 (58-328) cells/μl and 5.41 (4.80-5.74), respectively. After a median (IQR) duration of 27 (25-30) weeks on DTG, of the 131 participants with follow-up viral load data available, 129 (98%) had viral load less than 1000 copies/ml and among the 2 (2%) participants with viral load at least 1000 copies/ml, no emergent HIVDR was detected. We observed a significant increase in weight among the participants. The average weight gain was 5.25 kgs ( P < 0.0001). Baseline CD4 + cell count at least 200 cells/μl was significantly associated with at a smaller weight gain [odds ratio (OR) = 0.26; 95% confidence interval (CI) 0.12-0.58, P = 0.001].

Conclusion: We found high virological suppression and an increased weight among people initiating on DTG in a resource-limited setting. Encouragingly, HIVDR to DTG remains rare.

References

Moore C, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo C . ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based.... BMC Infect Dis. 2021; 21(1):5. PMC: 7809782. DOI: 10.1186/s12879-020-05672-6. View

Tate T, Willig A, Willig J, Raper J, Moneyham L, Kempf M . HIV infection and obesity: where did all the wasting go?. Antivir Ther. 2012; 17(7):1281-9. PMC: 3779137. DOI: 10.3851/IMP2348. View

Kouamou V, Varyani B, Shamu T, Mapangisana T, Chimbetete C, Mudzviti T . Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. AIDS Res Hum Retroviruses. 2020; 36(7):566-573. DOI: 10.1089/AID.2019.0232. View

Cahn P, Sierra Madero J, Arribas J, Antinori A, Ortiz R, Clarke A . Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2019; 83(3):310-318. PMC: 7043729. DOI: 10.1097/QAI.0000000000002275. View

Viani R, Ruel T, Alvero C, Fenton T, Acosta E, Hazra R . Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. J Pediatric Infect Dis Soc. 2019; 9(2):159-165. PMC: 7192395. DOI: 10.1093/jpids/piy139. View

Francois Venter W, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N . Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021; 35(Suppl 2):S183-S188. PMC: 8694575. DOI: 10.1097/QAD.0000000000003092. View

Lake J, Wu K, Bares S, Debroy P, Godfrey C, Koethe J . Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2020; 71(9):e471-e477. PMC: 7713693. DOI: 10.1093/cid/ciaa177. View

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses M, Antinori A, Dumitru I . Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383(9936):2222-31. DOI: 10.1016/S0140-6736(14)60084-2. View

Lahiri C, Xu Y, Wang K, Alvarez J, Sheth A, OHalloran J . Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. AIDS Res Hum Retroviruses. 2020; 37(6):461-467. PMC: 8213005. DOI: 10.1089/AID.2020.0197. View

10.

Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F . Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19):1807-18. DOI: 10.1056/NEJMoa1215541. View

11.

Kouamou V, Machekano R, Mapangisana T, Maposhere C, Munyati S, Mutsvangwa J . Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. AIDS Res Hum Retroviruses. 2022; 38(10):774-778. PMC: 9634981. DOI: 10.1089/AID.2021.0140. View

12.

Brown J, Nsakala B, Mokhele K, Rakuoane I, Muhairwe J, Urda L . Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2021; 23(3):287-293. PMC: 9293184. DOI: 10.1111/hiv.13189. View

13.

Orrell C, Hagins D, Belonosova E, Porteiro N, Walmsley S, Falco V . Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised,.... Lancet HIV. 2017; 4(12):e536-e546. DOI: 10.1016/S2352-3018(17)30095-4. View

14.

Bacha J, Dlamini S, Anabwani F, Gwimile J, Kanywa J, Farirai J . Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023; 42(7):576-581. PMC: 10259212. DOI: 10.1097/INF.0000000000003878. View

15.

Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S . Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9):816-826. DOI: 10.1056/NEJMoa1904340. View

16.

Kouamou V, Mavetera J, Manasa J, Ndhlovu C, Katzenstein D, McGregor A . Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. AIDS Res Hum Retroviruses. 2021; 37(10):776-783. DOI: 10.1089/AID.2020.0242. View

17.

Allahna E, Nicole D, Neha S, Hannah K, Jonah M, John O . Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study. J Acquir Immune Defic Syndr. 2022; 91(3):285-289. PMC: 9561234. DOI: 10.1097/QAI.0000000000003065. View

18.

Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S . Dolutegravir and weight gain: an unexpected bothering side effect?. AIDS. 2017; 31(10):1499-1500. DOI: 10.1097/QAD.0000000000001495. View

19.

Kouamou V, Manasa J, Katzenstein D, McGregor A, Ndhlovu C, Makadzange A . Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy. AIDS. 2019; 33(11):1729-1737. PMC: 6668919. DOI: 10.1097/QAD.0000000000002284. View

20.

Kingwara L, Inzaule S, Momanyi L, Jordan M, Nyanya W, Bowen N . Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya. AIDS. 2021; 36(4):611-613. DOI: 10.1097/QAD.0000000000003154. View